Literature DB >> 18779277

Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study.

Ji Young Kim1, Yae Jung Hyun, Yangsoo Jang, Byoung Kwon Lee, Jey Sook Chae, So Eui Kim, Hyun Yang Yeo, Tae-Sook Jeong, Dong Woon Jeon, Jong Ho Lee.   

Abstract

BACKGROUND: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a lipoprotein-bound enzyme that can release atherogenic isoprostanes from esterified phospholipids and that may be involved in inflammation and atherosclerosis.
OBJECTIVE: This study investigates the association between Lp-PLA(2) activity and coronary artery disease (CAD) in relation to oxidative stress markers, in particular urinary 8-epi-prostaglandin F(2alpha) (8-epi-PGF(2alpha)).
DESIGN: We conducted a case-control study in which the cross-sectional relation between Lp-PLA(2) activity, lipoproteins, and oxidative stress markers was determined in 799 patients with angiographically confirmed CAD and 925 healthy controls.
RESULTS: Lp-PLA(2) activity was significantly (P < 0.001) higher in CAD cases than in controls (32.9 +/- 0.46 and 29.7 +/- 0.42 nmol . mL(-1) . min(-1), respectively). Both elevated Lp-PLA(2) activity and urinary excretion concentrations of 8-epi-PGF(2alpha) were associated with greater CAD risk (P for trend < 0.001). Odds ratios for the upper quartiles of Lp-PLA(2) activity and 8-epi-PGF(2alpha).excretion were 2.47 (95% CI: 1.79, 3.40) and 2.19 (1.52, 3.15), respectively, after adjustment for sex, age, BMI, blood pressure, smoking and alcohol consumption status, and LDL and HDL cholesterol. When we examined the additive effect of both markers for CAD risk, the relation between 8-epi-PGF(2alpha) and CAD was weakened above the second quartile of Lp-PLA(2) activity. Moreover, Lp-PLA(2) activity was positively correlated with urinary excretion concentrations of 8-epi-PGF(2alpha) in controls (r = 0.277, P < 0.001) and cases (r = 0.202, P < 0.001) and with the tail moment of lymphocyte DNA (r = 0.213, P < 0.001) in controls.
CONCLUSION: This study shows an association of elevated Lp-PLA(2) activity with CAD risk in relation to oxidant stress and thus supports a proatherogenic role of Lp-PLA(2).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18779277     DOI: 10.1093/ajcn/88.3.630

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  19 in total

1.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Circulating Lp-PLA₂ activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy.

Authors:  Jean Kyung Paik; Minkyung Kim; Minjoo Kim; Yuna Yen; Hyeon Yeong Ahn; Sang-Hyun Lee; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2015

3.  Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women.

Authors:  Oh Yoen Kim; Jey Sook Chae; Jean Kyung Paik; Hee Sun Seo; Yangsoo Jang; Jean-Marc Cavaillon; Jong Ho Lee
Journal:  Age (Dordr)       Date:  2011-04-13

4.  Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.

Authors:  Rachel G Miller; Tina Costacou; Trevor J Orchard
Journal:  Diab Vasc Dis Res       Date:  2009-10-28       Impact factor: 3.291

5.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Authors:  Jane F Ferguson; Christine C Hinkle; Nehal N Mehta; Roshanak Bagheri; Stephanie L Derohannessian; Rhia Shah; Megan I Mucksavage; Jonathan P Bradfield; Hakon Hakonarson; Xuexia Wang; Stephen R Master; Daniel J Rader; Mingyao Li; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

Review 6.  F2-isoprostanes as an indicator and risk factor for coronary heart disease.

Authors:  Sean S Davies; L Jackson Roberts
Journal:  Free Radic Biol Med       Date:  2010-11-30       Impact factor: 7.376

7.  Replacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.

Authors:  Minjoo Kim; Se Ri Jeung; Tae-Sook Jeong; Sang-Hyun Lee; Jong Ho Lee
Journal:  J Lipid Res       Date:  2014-06-05       Impact factor: 5.922

8.  Levels of F2 isoprostane in Behcet's disease: Correlation with cardiometabolic risk factors.

Authors:  Gul Sagun; Aytekin Oguz; Banu Mesci; Banu Isbilen; Mukaddes Kavala; Havva Keskin; Mumtaz Takir; Sibel Zehra Aydin
Journal:  Redox Rep       Date:  2015-04-13       Impact factor: 4.412

9.  Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

Authors:  Jing Liu; Yuling Hong; Yue Qi; Fan Zhao; Dong Zhao
Journal:  N Am J Med Sci (Boston)       Date:  2011-10

10.  Effects of Gengnianchun on learning and memory ability, neurotransmitter, cytokines, and leptin in ovariectomized rats.

Authors:  Yan-Qiu Rao; Jun Li; Wen-Jun Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.